Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: Application to the evaluation of CYP2D6 drug interactions

Adrián LLerena, R. Berecz, Pedro Dorado, César Sanz De la Garza, María Jesús Norberto, Macarena Cáceres, José Ramón Gutiérrez

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

A high-pressure liquid chromatography with ultra-violet detection method for the simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma after liquid-liquid extraction has been developed. The limit of quantitation was 5 nmol/L, and the inter-day coefficient of variation was less than 8% for both compounds. The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively. Studies of analytical interference showed that the most commonly co-administered antidepressants and benzodiazepines did not interfere. The method was used for the determination of the plasma concentrations of a schizophrenic patient treated daily with an oral dose of 4.5 mg risperidone. The patient suffered severe extrapyramidal side-effects after adding risperidone to his previous medication of haloperidol and levomepromazine. The risperidone plasma concentration was well above the average (182 nmol/L), which suggests that a pharmacokinetic interaction occurred, presumably due to inhibition of the enzyme CYP2D6.

Original languageEnglish
Pages (from-to)213-219
Number of pages7
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume783
Issue number1
DOIs
Publication statusPublished - Jan 5 2003

Fingerprint

Drug interactions
Plasma (human)
Cytochrome P-450 CYP2D6
Risperidone
Liquid chromatography
Drug Interactions
Liquid Chromatography
Plasmas
Methotrimeprazine
High pressure liquid chromatography
Liquid-Liquid Extraction
Pharmacokinetics
Liquids
Haloperidol
Benzodiazepines
Antidepressive Agents
High Pressure Liquid Chromatography
Paliperidone Palmitate
Recovery
Enzymes

Keywords

  • 9-Hydroxyrisperidone
  • CYP2D6
  • Risperidone

ASJC Scopus subject areas

  • Biochemistry

Cite this

Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography : Application to the evaluation of CYP2D6 drug interactions. / LLerena, Adrián; Berecz, R.; Dorado, Pedro; De la Garza, César Sanz; Norberto, María Jesús; Cáceres, Macarena; Gutiérrez, José Ramón.

In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 783, No. 1, 05.01.2003, p. 213-219.

Research output: Contribution to journalArticle

LLerena, Adrián ; Berecz, R. ; Dorado, Pedro ; De la Garza, César Sanz ; Norberto, María Jesús ; Cáceres, Macarena ; Gutiérrez, José Ramón. / Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography : Application to the evaluation of CYP2D6 drug interactions. In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2003 ; Vol. 783, No. 1. pp. 213-219.
@article{2983b9cb127b450792fef5c6ba117532,
title = "Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: Application to the evaluation of CYP2D6 drug interactions",
abstract = "A high-pressure liquid chromatography with ultra-violet detection method for the simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma after liquid-liquid extraction has been developed. The limit of quantitation was 5 nmol/L, and the inter-day coefficient of variation was less than 8{\%} for both compounds. The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4{\%}, with an intra-day coefficient of variation of under 5 and 6{\%}, respectively. Studies of analytical interference showed that the most commonly co-administered antidepressants and benzodiazepines did not interfere. The method was used for the determination of the plasma concentrations of a schizophrenic patient treated daily with an oral dose of 4.5 mg risperidone. The patient suffered severe extrapyramidal side-effects after adding risperidone to his previous medication of haloperidol and levomepromazine. The risperidone plasma concentration was well above the average (182 nmol/L), which suggests that a pharmacokinetic interaction occurred, presumably due to inhibition of the enzyme CYP2D6.",
keywords = "9-Hydroxyrisperidone, CYP2D6, Risperidone",
author = "Adri{\'a}n LLerena and R. Berecz and Pedro Dorado and {De la Garza}, {C{\'e}sar Sanz} and Norberto, {Mar{\'i}a Jes{\'u}s} and Macarena C{\'a}ceres and Guti{\'e}rrez, {Jos{\'e} Ram{\'o}n}",
year = "2003",
month = "1",
day = "5",
doi = "10.1016/S1570-0232(02)00661-X",
language = "English",
volume = "783",
pages = "213--219",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography

T2 - Application to the evaluation of CYP2D6 drug interactions

AU - LLerena, Adrián

AU - Berecz, R.

AU - Dorado, Pedro

AU - De la Garza, César Sanz

AU - Norberto, María Jesús

AU - Cáceres, Macarena

AU - Gutiérrez, José Ramón

PY - 2003/1/5

Y1 - 2003/1/5

N2 - A high-pressure liquid chromatography with ultra-violet detection method for the simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma after liquid-liquid extraction has been developed. The limit of quantitation was 5 nmol/L, and the inter-day coefficient of variation was less than 8% for both compounds. The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively. Studies of analytical interference showed that the most commonly co-administered antidepressants and benzodiazepines did not interfere. The method was used for the determination of the plasma concentrations of a schizophrenic patient treated daily with an oral dose of 4.5 mg risperidone. The patient suffered severe extrapyramidal side-effects after adding risperidone to his previous medication of haloperidol and levomepromazine. The risperidone plasma concentration was well above the average (182 nmol/L), which suggests that a pharmacokinetic interaction occurred, presumably due to inhibition of the enzyme CYP2D6.

AB - A high-pressure liquid chromatography with ultra-violet detection method for the simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma after liquid-liquid extraction has been developed. The limit of quantitation was 5 nmol/L, and the inter-day coefficient of variation was less than 8% for both compounds. The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively. Studies of analytical interference showed that the most commonly co-administered antidepressants and benzodiazepines did not interfere. The method was used for the determination of the plasma concentrations of a schizophrenic patient treated daily with an oral dose of 4.5 mg risperidone. The patient suffered severe extrapyramidal side-effects after adding risperidone to his previous medication of haloperidol and levomepromazine. The risperidone plasma concentration was well above the average (182 nmol/L), which suggests that a pharmacokinetic interaction occurred, presumably due to inhibition of the enzyme CYP2D6.

KW - 9-Hydroxyrisperidone

KW - CYP2D6

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=0037419494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037419494&partnerID=8YFLogxK

U2 - 10.1016/S1570-0232(02)00661-X

DO - 10.1016/S1570-0232(02)00661-X

M3 - Article

C2 - 12450541

AN - SCOPUS:0037419494

VL - 783

SP - 213

EP - 219

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 1

ER -